

HOLLAND & KNIGHT LLP

One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400

404-817-8500
404-881-0470 Fax
www.hklaw.com

Annapolis
Atlanta
Belthesda
Boston
Brenton
Chicago*
Fort Lauderdale
Jacksonville
Lakeland
Los Angeles
Miami
New York
Northern Virginia
Orlando
Portland
Providence
St. Petersburg
San Antonio

San Francisco
Seattle
Tallahassee
Tampa
Washington, D.C.
West Palm Beach

International Offices:
Caracas**
Helsinki
Mexico City
Rio de Janeiro
São Paulo
Tel Aviv**
Tokyo

*Holland & Knight LLC
**Representative Office

RECEIVED
CENTRAL FAX CENTER

FEB 19 2004

OFFICIAL

FACSIMILE**TO:**

	U.S. Patent and Trademark Office	703-872-9306
NAME	COMPANY/FIRM	FAX NUMBER
Alexandria	VA	703-308-1202
CITY	STATE	(TELEPHONE NUMBER)

FROM:

Patrea L. Pabst	404-817-8473
NAME	TELEPHONE
	TOTAL PAGES (Including Cover Sheet)

FOR THE RECORD:

DATE: February 19, 2004	URGENCY: <input type="checkbox"/> SUPER RUSH	<input type="checkbox"/> RUSH	<input type="checkbox"/> REGULAR
FAXED BY:	FILE #: 085337/00006	CLIENT NAME: CP 103	
CONFIRMED: <input type="checkbox"/> YES <input type="checkbox"/> NO	NAME:	TIME:	

If you did not receive all of
the pages or find that they
are illegible, please call
(404) 817-8500

CONFIDENTIALITY NOTICE: This facsimile, along with any documents, files, or attachments, may contain information that is confidential, privileged, or otherwise exempt from disclosure. If you are not the intended recipient or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, printing, distribution or use of any information contained in or attached to this facsimile is strictly prohibited. If you have received this facsimile in error, please immediately notify us by facsimile or by telephone collect at the numbers stated above, and destroy the original facsimile and its attachments without reading, printing, or saving in any manner. Your cooperation is appreciated. Thank you.

MESSAGE:

Applicant: Mark Hirsh

Serial No.: 10/012,202

Art Unit: 1615

Filed: December 5, 2001

Examiner: H. N. Sheikh

For: **COMPOSITION CONTAINING BOTH SEDATIVE AND NON-SEDATIVE
ANTHISTAMINES**

1617926_v1

PTO/SB/21 (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/012,202
	Filing Date	December 5, 2001
	First Named Inventor	Mark Hirsh
	Art Unit	1615
	Examiner Name	H. N. Sheikh
Total Number of Pages in This Submission	Attorney Docket Number	CP 103

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input checked="" type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Patrea L. Pabst, Esq., Reg. No. 31,284 Holland & Knight LLP Suite 2000, One Atlantic Center, 1201 West Peachtree Street, N.E., Atlanta, GA 30309-3400
Signature	
Date	February 19, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Jean Hicks
Signature	<i>Jean Hicks</i>
Date	February 19, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 165.00)

Complete If Known

Application Number	10/012,202
Filing Date	December 5, 2001
First Named Inventor	Mark Hirsh
Examiner Name	H. N. Sheikh
Art Unit	1615
Attorney Docket No.	CP 103

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number
Deposit
Account
Name

50-1868

Holland & Knight LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)			(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent	-20* =	X	
Multiple Dependent	-3** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,620	1812 2,620	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	165.00
1403 280	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1480 130	1480 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(g)	
1808 180	1808 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 165.00)**SUBMITTED BY**

Name (Print/Type)	Patrea L. Pabst	Registration No. (Attorney/Agent)	31,284	Telephone	(404) 817-8473
Signature		Date	February 19, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
CENTRAL FAX CENTER

FEB 19 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appellant: Mark Hirsh

Serial No.: 10/012,202

Art Unit: 1615

Filed: December 5, 2001

Examiner: H. N. Sheikh

For: *COMPOSITION CONTAINING BOTH SEDATIVE AND NON-SEDATIVE
ANTIHISTAMINES*

Box Appeal Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

APPEAL BRIEF

Sir:

This is an appeal from the final rejection of claims 1-29 in the Office Action mailed July 21, 2003, in the above-identified patent application. A Notice of Appeal was mailed on December 19, 2003, along with a Response to the Office Action. The Commissioner is hereby authorized to charge \$165.00 for the filing of this Appeal Brief, which is the appropriate fees for a small entity, to Deposit Order Account No. 50-1868. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-1868.

CP 103
85317/6

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

(1) REAL PARTY IN INTEREST

The real party in interest of this application is the assignee Peirce Management, LLC, Wellesley, MA.

(2) RELATED APPEALS AND INTERFERENCES

There are no related appeals or interferences known to appellant, the undersigned, or appellant's assignee which directly affects, which would be directly affected by, or which would have a bearing on the Board's decision in this appeal.

(3) STATUS OF CLAIMS ON APPEAL

Claims 1-29 are pending and on appeal.

(4) STATUS OF AMENDMENTS

The claims were last amended in the amendment mailed on May 15, 2003. Appendix I sets forth the claims on appeal.

(5) SUMMARY OF THE INVENTION

A combination formulation of (1) a non-sedating antihistamine which inhibits histamine release for a period of either 4 to 12 hours or 10 to 20 hours and (2) a sedating antihistamine which inhibits histamine release for a period of either 10 to 20 or 4 to 12 hours, which is not released from the formulation for 6 to 10 or 8 to 12 hours after administration. See pages 7 to 8.

(6) ISSUES ON APPEAL

The issues presented on appeal are:

(a) whether claims 1-29 are obvious under 35 U.S.C. 103 over U.S. Patent No. 5,451,409 to Rencher et al. ("Rencher"); and

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

(b) whether claims 1-29 are obvious under 35 U.S.C. 103 over U.S. Patent No. 5,827,852 to Russell, et al., or U.S. Patent No. 5,648,358 to Mitra, et al. in combination with Rencher.

(8) ARGUMENTS

(a) The Claimed Invention

The claims define a biphasic antihistamine composition in daily oral uni-dosage or divided dosage form and a method of making and using the composition. The dosage form contains **two monophasic parts**, each having an active ingredient which is either a sedating antihistamine or a non-sedating antihistamine (p. 7, line 15 to p. 8, line 9). The claimed composition has the advantage of (1) avoiding sedating effects of sedating antihistamine during the day time and (2) taking the full advantage of sedating antihistamine in the night time (p. 9, lines 5-13), while only needing to be administered once a day. The claimed composition achieves this advantage by being formulated so that only non-sedating antihistamine is released in the day, and only sedating antihistamine is released at night (p. 8, line 10 to p. 9, line 4). Various delayed or sustained release formulations and coatings (p. 10, lines 9-25; p. 13, lines 1-13; p. 13, line 18 to p. 28, Examples 1-3) are used to achieve this release profile.

Dependent claims are drawn to compositions comprising specific sedating antihistamines (claims 2, 3, 14 and 15) or a therapeutically effective amount of an additional agent (claims 8, 19, 25, 28 and 29). The composition can have a specific release profile of the sedating or non-sedating antihistamine or the additional agent (claims 4-7 and 16-18). The sedating or non-sedating antihistamine can be formulated into a sustained release form or a delayed release form (claims 24-27 and 29) using at

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

least one delayed release control polymer or at least one sustained release control polymer defined therein.

As shown in Examples 1-3, procedures are taken to ensure the biphasic feature of the composition such that the sedating antihistamine is released in the night or evening time but not released in the day time and the non-sedating antihistamine is released in the day time but not released in the night time.

(b) Rejections Under 35 U.S.C. § 103

The Legal Standard

The U.S. Patent and Trademark Office has the burden under 35 U.S.C. § 103 to establish a *prima facie* case of obviousness. *In re Warner et al.*, 379 F.2d 1011, 154 U.S.P.Q. 173, 177 (C.C.P.A. 1967), *In re Fine*, 837 F.2d 1071, 1074, 5 U.S.P.Q.2d 1596, 1598-99 (Fed. Cir. 1988). In rejecting a claim under 35 U.S.C. § 103, the Examiner must establish a *prima facie* case that: (i) the prior art suggests the claimed invention; and (ii) the prior art indicates that the invention would have a reasonable likelihood of success. *In re Dow Chemical Company*, 837 F.2d 469, 5 U.S.P.Q.2d 1529 (Fed. Cir. 1988).

The prior art must provide one of ordinary skill in the art with the motivation to make the proposed modifications needed to arrive at the claimed invention. *In re Geiger*, 815 F.2d 686, 2 U.S.P.Q.2d 1276 (Fed. Cir. 1987); *In re Lalu and Foulletier*, 747 F.2d 703, 705, 223 U.S.P.Q. 1257, 1258 (Fed. Cir. 1984). Claims for an invention are not *prima facie* obvious if the primary references do not suggest all elements of the claimed invention and the prior art does not suggest the modifications that would bring the primary references into conformity with the application claims. *In re Fritch*, 23 U.S.P.Q.2d, 1780 (Fed. Cir. 1992). *In re Laskowski*, 871 F.2d 115 (Fed. Cir. 1989). The

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

Court of Appeals for the Federal Circuit warned that “the best defense against the subtle but powerful attraction of a hindsight-based obviousness analysis is rigorous application of the requirement for showing of the teaching or motivation to combine prior art references.” *In re Dembiczak*, 175 F.3d 994 at 999 (Fed. Cir. 1999). The “question is whether there is something in the prior art as a whole to suggest the desirability, and thus the obviousness, of making the combination. *WMS Gaming, Inc. v International Game Technology*, 184 F.3d 1339 at 1355 (Fed. Cir. 1999). “[T]he showing must be clear and particular.” *In re Dembiczak*, 175 F.3d 994 at 999 (Fed. Cir. 1999). Although with the answer in hand, the “solution” now appears obvious, that is not the test. The references must themselves lead those in the art to what is claimed. And in this case, there is simply no such teaching.

The Prior Art

Rencher

Rencher describes a single “homogeneous matrix” containing one or more actives, from which each active component is released at an appropriate rate to provide the desired activity over a period of 2 to 24, preferably 8 to 12 hours (col. 2, lines 21-27). The formulation uses a polymer blend of hydroxypropyl cellulose (HPC) and hydroxyethyl cellulose (HEC) to control the release rate of the active components (col. 1, line 60 to col. 2, line 5). It is important to note that the composition, upon administration, provides sustained; *not delayed*, release, releasing the active component at a rate to provide the desired activity over a period of 2 to 24 hours (col. 2, lines 26-27). The active component is released immediately at an effective level and remains such over a period of 2 to 24 hours. This is clearly seen in Tables 6 and 8, which shows that the

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

composition can release 15 to 26 percent of the active component within 30 minutes after administration.

Russell

Russell describes a pharmaceutical composition suitable for coating a drug for treating cold, cough, allergy, and flu symptoms (col. 2, lines 42-67). The active ingredient can be an antihistamine (col. 5, lines 37-42). The composition can be formed of triturate active ingredients which are "blended together" (col. 7, line 45 to col. 8, line 67, particularly col. 8, lines 33-35, Examples I-III). The active ingredients in a composition of a blend of triturate active ingredients do not distinguish one from another in terms of the timing and the rate of release. Therefore, the composition described in Russell, without more, would not delay the release of any of the active ingredients. It certainly cannot prevent the release of one of the active ingredient in the day time.

Mitra

Mitra describes antihistamine preparations which must contain caffeine, a stimulant (col. 2, line 24). This is the antithesis of what applicants claim: a biphasic composition that allows one to obtain the benefit of an antihistamine while sleeping, and the benefit of a non-sedating antihistamine while active. Indeed the goal of Mitra's formulation is to prevent the sleepiness due to the use of an antihistamine! (see col. 2, lines 61-67)

The Art Alone or in Combination

Rencher fails to make obvious the claimed subject matter because Rencher does not recognize the benefit of a formulation containing both a sedating antihistamine and a non-sedating antihistamine, which are released at different time periods. Moreover,

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

Rencher teaches making a homogeneous composition of the active ingredients. In contrast, as the foregoing discussion shows, a biphasic composition as defined in any of the claims 1-29 is necessary to achieve the release profile defined in claims of the present application. Therefore, even if one could find a reference providing the motivation to combine a sedating with a non-sedating antihistamine, Rencher would not lead one of ordinary skill in the art to have a reasonable expectation of success of the claimed composition and method of using the composition. Further, in emphasizing a homogeneous composition, Rencher teaches away from the claimed biphasic composition.

Russell teaches forming a simple blend of triturate active ingredients while Rencher teaches forming a homogenous composition. Therefore, Russell in combination with Rencher, fails to teach one skilled in the art to make a biphasic composition, for delivery of a sedating antihistamine during the night and a non-sedating antihistamine during the day time.

Accordingly, Russell in view of Rencher would not render claims 1-29 *prima facie* obvious under 35 U.S.C. 103.

Mitra's formulation *never allows one to sleep - the caffeine is a stimulant*. If one combined Mitra's formulation into a biphasic composition, one would not achieve appellant's goal. Therefore the claimed subject matter, alone or in combination with Rencher cannot be obvious from Mitra.

The examiner's rejections have been conclusory and apparently made only by reference to claim 1. None of the prior art defines time periods in which antihistamine activity – either sedating or non-sedating activity is desirable, as required by the

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

independent claims, as well as claims 4, 5, 16, 17, and 22. None of the art teaches combining a sedating and a non-sedating antihistamine, much less the selection of the specific medications defined by claims 2, 3, 14, and 15. None of the art recognizes that one may add other medications, such as an analgesic that is released in only one or both of the two phases of the formulation, as defined by claims 25, 26, 28 and 29, for example, so that it is released immediately or in a delayed or sustained release fashion. Indeed, the examiner appears to have ignored the additional limitations of the dependent claims.

(9) SUMMARY AND CONCLUSION

In summary, none of the art motivates one skilled in the art to make a biphasic composition containing a sedating antihistamine in a first portion and a non-sedating antihistamine in a second portion where release is delayed.

The examiner has used hindsight to provide motivation. This is improper, however. It is well established that the motivation *must* come from the references themselves. In this case, at least one of the references actually teaches away from what applicants have developed, and none recognize the potential benefit or desirability of a two phase formulation. Therefore the subject matter of claims 1-29 is not obvious.

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

For the foregoing reasons, Appellant submits that the claims 1-29 are patentable.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: December 18, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center, Suite 2000
1201 West Peachtree Street
Atlanta, Georgia 30309-3400
(404) 817-8473
(404) 817-8588 (fax)

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

Appendix: Claims On Appeal

1. (original) A biphasic antihistamine composition in daily oral uni-dosage or divided dosage form which comprises:

(a) a therapeutically effective amount of a sedating antihistamine to inhibit histamine release for a duration of about 4 to 12 hours, and

(b) a therapeutically effective amount of non-sedating antihistamine to inhibit histamine release for a duration of 10 to 20 hours, with a delayed release 6 to 10 hours after ingestion.

2. (original) The antihistamine composition defined in claim 1 wherein the sedating antihistamine is selected from the group consisting of brompheniramine, chlorpheniramine, debrompheniramine, dexchlorpheniramine, carbinoxamine, clemastine, diphenhydramine, pyrilamine, tripeleminamine, triprolidine, methdilazine, bromodiphenhydramine, promethazine, azatadine, cyproheptadine, diphenylpyraline, doxylamine, trimeprazine, phenindamine, ketotifen, hydroxyzine, tazifylline, temelastine, meclizine, acrivastine, setastine, oxatomide, mequitazine, levocabastine, lodoxamide, AHR 11325, phenindamine, azelastine, and ebastine, or a pharmaceutically acceptable salt thereof.

3. (original) The antihistamine composition defined in claim 1 wherein the non-sedating antihistamine is selected from the group consisting of fexofenadine, loratadine, descarboethoxy loratadine, astemizole, norastemizole, desmethylastemizole, cetirizine, acrivastine, and temelastine, or a pharmaceutically acceptable salt thereof.

4. (original) The antihistamine composition defined in claim 1 wherein the sedating antihistamine has a duration of activity of about 6 to 10 hours.

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

5. (original) The antihistamine composition defined in claim 1 wherein the non-sedating antihistamine has a duration of activity of about 12 to 18 hours.
6. (original) The antihistamine composition defined in claim 1 wherein the sedating antihistamine is releasable immediately or up to 1 hour following administration.
7. (original) The antihistamine composition defined in claim 1 wherein the non-sedating antihistamine is releasable immediately or up to 1 hour following administration.
8. (original) The antihistamine composition defined in claim 1 which further comprises a therapeutically effective amount of at least one agent selected from the group consisting of an analgesic agent, an antitussive agent, an expectorant, an anti-inflammatory agent, an anti-pyretic agent and a decongestant.
9. (original) A method of inhibiting the release of histamine in a patient which comprises the step of administering to the patient, a therapeutically effective amount of the antihistamine composition defined in claim 1.
10. (original) The method of inhibiting the release of histamine defined in claim 9 wherein the antihistamine composition is administered during the evening or night and the sedating antihistamine is immediately released.
11. (original) The method of inhibiting the release of histamine defined in claim 9 wherein the antihistamine composition is administered during the evening or night and the non-sedating antihistamine is released the next day, 6 to 10 hours following administration.
12. (original) The method of inhibiting the release of histamine defined in claim 9 wherein the patient suffers from allergic reaction, allergic rhinitis, cold or flu.

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

13. (original) A biphasic antihistamine composition in daily oral uni-dosage or divided dosage form which comprises:

(a) a therapeutically effective amount of a non-sedating antihistamine to inhibit histamine release for a duration of about 10 to 20 hours, and

(b) a therapeutically effective amount of sedating antihistamine to inhibit histamine release for a duration of 4 to 12 hours, with a delayed release, 8 to 12 hours after ingestion.

14. (original) The antihistamine composition defined in claim 13 wherein the non-sedating antihistamine is selected from the group consisting of fexofenadine, loratadine, descarboethoxy loratadine, astemizole, norastemizole, desmethylastemizole, cetirizine, acrivastine, and temelastine, or a pharmaceutically acceptable salt thereof.

15. (original) The antihistamine composition defined in claim 13 wherein the sedating antihistamine is selected from the group consisting of brompheniramine, chlorpheniramine, debrompheniramine, dexchlorpheniramine, carbinoxamine, clemastine, diphenhydramine, pyrilamine, tripeleennamine, tripolidine, methdilazine, bromodiphenhydramine, promethazine, azatadine, cyproheptadine, diphenylpyraline, doxylamine, trimeprazine, phenindamine, ketotifen, hydroxyzine, tazifylline, temelastine, meclizine, acrivastine, setastine, oxatomide, mequitazine, levocabastine, lodoxamide, AHR 11325, phenindamine, azelastine, and ebastine, or a pharmaceutically acceptable salt thereof.

16. (original) The antihistamine composition defined in claim 13 wherein the non-sedating antihistamine has a duration of activity of about 12 to 18 hours.

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

17. (original) The antihistamine composition defined in claim 13 wherein the sedating antihistamine has a duration of activity of about 6 to 10 hours.

18. (original) The antihistamine composition defined in claim 13 wherein the non-sedating antihistamine is releasable immediately or up to 1 hour following administration.

19. (original) The antihistamine composition defined in claim 13 which further comprises at least one agent selected from the group consisting of an analgesic agent, an antitussive agent, an expectorant, an anti-inflammatory agent, an anti-pyretic agent and a decongestant.

20. (original) A method of inhibiting the release of histamine in a patient which comprises the step of administering to the patient, a therapeutically effective amount of the antihistamine composition defined in claim 13.

21. (original) The method of inhibiting the release of histamine defined in claim 20 wherein the antihistamine composition is administered during the day and the non-sedating antihistamine is immediately released.

22. (original) The method of inhibiting the release of histamine defined in claim 20 wherein the antihistamine composition is administered during the day and the sedating antihistamine is released in the evening or night, 8 to 12 hours following administration.

23. (original) The method of inhibiting the release of histamine defined in claim 20 wherein the patient suffers from allergic reaction, allergic rhinitis, cold or flu.

24. (original) The antihistamine composition defined in claim 1 wherein the delayed release portion is achieved by coating a core or granulations with at least one delayed release control polymer selected from the group consisting of ethyl cellulose,

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

cellulose acetate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate, azo polymers, pectin, chitosan, amylose, guar gum, and zein or combination thereof.

25. (original) The antihistamine composition defined in claim 8 wherein the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant is in a sustained release form.

26. (original) The antihistamine composition defined in claim 25 wherein the sustained release effect is achieved by formulating the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant with a sustained-release control polymer selected from the group consisting of methyl cellulose, ethyl cellulose, wax, gums, cellulose acetate, cellulose acetate phthalate, hydroxypropylmethylcellulose succinate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate and combination thereof.

27. (original) The antihistamine composition defined in claim 13 wherein the delayed release portion is achieved by coating a core or granulations with at least one delayed release control polymer selected from the group consisting of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate, azo polymers, pectin, chitosan, amylose, guar gum, and zein or combination thereof.

28. (previously presented) The antihistamine composition defined in claim 19 wherein the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant is in an immediate release form or in a sustained release form.

29. (original) The antihistamine composition defined in claim 28 wherein the sustained release effect is achieved by formulating the analgesic agent, antitussive agent, expectorant, anti-inflammatory agent or decongestant with a sustained-release control polymer selected from the group consisting of methyl cellulose, ethyl cellulose, wax, gums, cellulose acetate, cellulose acetate phthalate, hydroxypropylmethylcellulose succinate, polyvinyl acetate phthalate, acrylic acid polymers and copolymers, polymers or copolymers of methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate, vinyl acetate and combination thereof.

U.S.S.N. 10/012,202
Filed: December 5, 2001
APPEAL BRIEF

TABLE OF CONTENTS

- (1) REAL PARTY IN INTEREST**
- (2) RELATED APPEALS AND INTERFERENCES**
- (3) STATUS OF CLAIMS ON APPEAL**
- (4) STATUS OF AMENDMENTS**
- (5) SUMMARY OF THE INVENTION**
- (6) ISSUES ON APPEAL**
- (7) GROUPING OF CLAIMS**
- (8) ARGUMENTS**
 - (a) The Claimed Invention**
 - (a) The Claimed Invention**
 - (b) Rejections Under 35 U.S.C. § 103**
- (9) SUMMARY AND CONCLUSION**

Certificate of Mailing

Appendix I: Claims On Appeal

Table of Contents

1711889_v1